Hamill John P. 4

What Happened
John P. Hamill, Senior VP, Chief Financial Officer and Principal Financial & Accounting Officer of Aprea Therapeutics (APRE), was granted equity awards on March 12, 2026: 10,095 restricted stock units (RSUs) and 40,380 option-style awards (reported as a derivative). Both grants were reported at $0.00 consideration (i.e., awarded, not purchased). These awards are compensation grants, not open-market purchases or sales.

Key Details

• Transaction date: March 12, 2026; Form 4 filed March 16, 2026 (timely filed). Accession: 0001104659-26-028653.
• Transaction codes: A = Award/Grant; second grant reported as a derivative award.
• Amounts & price: 10,095 RSUs @ $0.00; 40,380 derivative awards @ $0.00 (total 50,475 units).
• Vesting (from filing footnotes):
  • RSUs (F1): Vest and settle in common stock in three equal annual installments beginning March 12, 2027, subject to continued employment and possible acceleration.
  • Options/derivative (F2): 25% vest on March 12, 2027; remaining options vest ratably over the following 36 months, subject to continued employment and possible acceleration.
• Shares owned after transaction: Not disclosed in the provided filing.
• Filing timeliness: Filed within the SEC’s 2-business-day window (timely).

Context
RSUs convert into actual shares only as they vest and are settled; option awards will vest per the schedule before becoming exercisable/convertible into shares. These grants are typical executive compensation and do not represent immediate buying or selling of stock. They may dilute existing shareholders when vested/exercised, but the filing itself does not indicate the insider’s view of the company’s near-term stock prospects.